Year: 2024
Type: article
Study design: Observational Study
Abstract: Chronic myeloid leukemia (CML) typically occurs in late adulthood. Pediatric CML is a rare form of leukemia. In all age groups, the characteristic genetic driver of the disease is the BCR::ABL1 fusion gene. However, additional genomic events contribute to leukemic transformation, which is not yet well-characterized in pediatric CML. We investigated the mutational landscape of pediatric CML to determine whether predisposing germline variants may play a role in early-age disease development. Whole exome sequencing and targeted sequencing were performed in pediatric and adult CML samples to identify age-related germline and somatic variants in addition to the BCR::ABL1 translocation. Germline variants were detected in about 60% of pediatric patients with CML, with predominantly hematopoietic genes affected, most frequently ASXL1, NOTCH1, KDM6B, and TET2. The number of germline variants was significantly lower in adult patients with CML. If only confirmed pathogenic variants were regarded as cancer-predisposing variants, the occurrence was ~ 10% of pediatric CML, which is comparable to other hematological malignancies and most childhood cancer entities in general. We hypothesize that the interaction with the strong oncogene BCR::ABL1 may also favor the development of leukemia by weaker variants in the same genes. In pediatric patients, the germline variants of genes associated with clonal hematopoiesis may increase the likelihood that an incidental BCR::ABL1 translocation triggers the early manifestation of CML.
Source: Molecular Cancer
Institutions: Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen, Humboldt-Universität zu Berlin, Freie Universität Berlin, Charité - Universitätsmedizin Berlin, Universität Ulm, University Hospital Ulm, Munich Leukemia Laboratory (Germany), Technische Universität Dresden, Friedrich-Alexander-Universität Erlangen-Nürnberg
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,890
Awards: G1509938299, FOR 5659: TARGETMPN: Zielgerichtetes Vorgehen gegen KrankheitsPersistenz und Progression bei myeloproliferativen Neoplasien (MPN), MyPred - Entwicklung von Früherkennungs- und Behandlungsstrategien für junge Menschen mit Prädisposition für myeloische Neoplasien: Entdeckung und Charakterisierung genetischer Veränderungen bei der pädiatrischen chronischen myeloischen Leukämie, G7578079922
OpenAlex ID: W4402892004
